Table 2.
Average reversal score predicted anti-SARS-CoV-2 compounds in vitro efficacy testing.
| Compound | IC50 (μM) | CC50 (μM) | SI index |
|---|---|---|---|
| AZD-1208 | 27.34 | > 50 | 1.83 |
| Sitagliptin | > 50 | > 50 | 1.00 |
| SR-2640 hydrochloride | 24.23 | > 50 | 2.06 |
| Levetiracetam | > 50 | > 50 | 1.00 |
| Meclofenamic acid sodium salt | 35.13 | > 50 | 1.42 |
| Chloroquine | 11.29 | > 150 | 13.29 |
| Lopinavir | 12.63 | > 50 | 3.96 |
| Remdesivir | 8.58 | > 50 | 5.83 |
IC50, CC50, and SI index were calculated of each compound in SARS-CoV-2 infected in Vero cells. . No compound exhibited reasonable anti-SARS-CoV-2 activities due to high IC50 across board.